WebTreadwell Therapeutics Announces Fast Track Designation Granted by the FDA to CFI-400945 for the Treatment of Acute Myeloid Leukemia prnewswire.com WebShane Burgess, OD, MBA Chief Executive Officer and Managing Director. A co-founder and managing director of TIO Bioventures, Dr. Shane Burgess brings significant …
Treadwell Therapeutics Announces US FDA Clearance of IND …
WebJun 2, 2024 · NEW YORK-- ( BUSINESS WIRE )-- Treadwell Therapeutics, a clinical-stage biotechnology company developing novel therapeutics for highly aggressive cancers, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to evaluate its third therapeutic candidate, CFI … WebDec 27, 2024 · Dr. Shane Burgess brings significant entrepreneurial and management experience in the healthcare industry to his role as Co-CEO of Treadwell. In ad Read More Contact Shane Burgess's Phone Number and Email Last Update 12/27/2024 11:49 AM Email s***@tiobioventures.com Engage via Email Contact Number (***) ***-**** Engage via … dni simple trust
Shane Burgess Profiles Facebook
WebShane Burgess is the co-CEO of Treadwell Therapeutics. Shane has also previously worked with VoltSafe, Hyalos Inc., and was a co-founder at FYidoctors. Shane has been working in the medical industry for over 12 years and has been instrumental in the development and success of several startups. Shane is a passionate advocate for patients and is ... WebJan 13, 2024 · Treadwell Therapeutics, a NYC-based clinical-stage oncology company exploiting cancer cells’ vulnerabilities to develop small molecules to address unmet needs in patients with cancer, raised an... WebDec 27, 2024 · Dr. Shane Burgess brings significant entrepreneurial and management experience in the healthcare industry to his role as Co-CEO of Treadwell. In addition to co … dni skincare